{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"ara-290","verification":{"valid":true,"entries":33,"head":"147e3dc4c198cc398066fc054405d1c174ef6fb171b80d854a9d832ec3ac139e"},"count":33,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23168581/","title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study","quote":"The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo","claim_ids":["c4"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"genesis","hash":"05348f17e26a6d4e055d4423b0f53bc437601d0b73fb18bbf436953cc17761f5","plain":"The first randomized, blinded, placebo-controlled test in people, in sarcoidosis patients with small-fiber nerve damage, with better symptom scores by week four. A pilot: small, short, and resting on what people reported rather than on anything imaged."},{"id":"s2","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT02039687","title":"Phase 2 Dose Ranging Study of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis","quote":"activate repair mechanisms and accelerate healing, including the nerve damage that can be associated with sarcoidosis","claim_ids":["c5"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"05348f17e26a6d4e055d4423b0f53bc437601d0b73fb18bbf436953cc17761f5","hash":"a8356e28c4b4b0efbde1fa64e2642bfe0c7c0b3b743ec4edbd879f6a38142150","plain":"The registry entry for the dose-ranging study. The quoted line is the sponsor describing what the compound is meant to do, not a finding. Its value is documenting that the study existed, at which doses, and in whom."},{"id":"s3","type":"pubmed","url":"https://research.manchester.ac.uk/en/publications/cibinetide-improves-corneal-nerve-fiber-abundance-in-patients-wit/","title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","quote":"The placebo-corrected mean change from baseline CNFA at day 28 was 697 (159, 1236; P = 0.012)","claim_ids":["c5"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"a8356e28c4b4b0efbde1fa64e2642bfe0c7c0b3b743ec4edbd879f6a38142150","hash":"c111a05375510ba36fc9cc8a617391452fd8f79c71cc278191398f5339647fb2","plain":"A university repository record of the dose-ranging trial's headline result: at day 28 the middle dose beat placebo on how much nerve fiber the cornea held. Corneal imaging stands in for nerve health elsewhere in the body, and 28 days is a short window."},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25387363/","title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","quote":"Subjects receiving ARA 290 exhibited an improvement in hemoglobin A1c and lipid profiles throughout the 56 d observation period.","claim_ids":["c6"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"c111a05375510ba36fc9cc8a617391452fd8f79c71cc278191398f5339647fb2","hash":"336948d1d24ae88273efef9731c92bf25302b18b463ba23b4c101834958e2154","plain":"A trial in people with type 2 diabetes over 56 days, reporting better blood sugar and blood fat readings alongside nerve symptoms. Those are secondary readings from a small study, and none of them is something a person would feel directly."},{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/","title":"ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response","quote":"ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response","claim_ids":["c7"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"336948d1d24ae88273efef9731c92bf25302b18b463ba23b4c101834958e2154","hash":"e20baa664429fb3b5d71035ff6c6042b8d4755b542ef78a0a9fdc127c8ea62ac","plain":"Animals with deliberately injured nerves. Pain sensitivity fell in step with the dose and stayed down, while the spinal immune cells that keep pain running went quiet. This is the mechanism story underneath the human trials, told in rodents."},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26683514/","title":"A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets","quote":"Secretion of pro-inflammatory cytokines (IL-6, IL-12, and TNF-alpha) from macrophages was significantly inhibited by ARA 290.","claim_ids":["c8"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"e20baa664429fb3b5d71035ff6c6042b8d4755b542ef78a0a9fdc127c8ea62ac","hash":"f4d50f634a008096446e3397f890b428d3994b01b6a7b69c608ba47d7ff70c32","plain":"Immune cells and transplanted insulin-producing cell clusters, not people. Three inflammatory signals dropped and the transplanted cells survived better. This is where the idea of a broad tissue-protecting effect comes from."},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20660739/","title":"Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin","quote":"HBSP protects cardiomyocytes from apoptosis and leads to a favorable outcome in failing hearts","claim_ids":["c9"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"f4d50f634a008096446e3397f890b428d3994b01b6a7b69c608ba47d7ff70c32","hash":"10edbf249e1bdd1439a9ab2cad70732972937874028d1ce2ac95803d39112f9f","plain":"Heart tissue rather than nerve: the same class of peptide kept heart muscle cells from dying and improved outcomes in failing hearts. It sits here as evidence the protective effect is not nerve-specific, though it is animal work on a related peptide."},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15456912/","title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","quote":"EpoR and betacR comprise a tissue-protective heteroreceptor.","claim_ids":["c1","c3"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"10edbf249e1bdd1439a9ab2cad70732972937874028d1ce2ac95803d39112f9f","hash":"f5928e240aa0f625a0b8f00c523b043a9dca49b4d0114de7f6ec50a06d206770","plain":"The 2004 paper that defined the receptor. It showed erythropoietin's tissue-protecting side runs through a different receptor pairing than its blood-cell-making side, which is the finding that made a non-blood-stimulating peptide possible at all."},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18676614/","title":"Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin","quote":"the tissue-protective activities of EPO are mimicked by small, nonerythropoietic peptides that simulate a portion of EPO's three-dimensional structure.","claim_ids":["c1","c3"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"f5928e240aa0f625a0b8f00c523b043a9dca49b4d0114de7f6ec50a06d206770","hash":"be4b56f5ab3fb5bb5e297999140cdd19fce16559b081c6430d572a5ec99f85fd","plain":"The follow-up work showing that small peptides copying one face of the erythropoietin molecule reproduce its protective effects without the blood-cell effects. This is the paper ARA-290's eleven amino acids came out of."},{"id":"s11","type":"news","url":"https://superpower.com/guides/ara-290","title":"ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor","quote":"not stimulate erythropoiesis or raise red blood cell counts","claim_ids":["c2"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"be4b56f5ab3fb5bb5e297999140cdd19fce16559b081c6430d572a5ec99f85fd","hash":"093b10575a3011a8ca851746d23f2966b18b41a4eed8231b51fa251506e9e185","plain":"A commercial explainer page, not a study. Its point, that red blood cell counts do not rise, traces back to trial data, so take the claim from the trials rather than from a page written to sell adjacent products."},{"id":"s12","type":"news","url":"https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/","title":"Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients","quote":"cibinetide (ARA 290) was shown to promote significant corneal nerve and improve pain and functional capacity in a clinical trial with sarcoidosis patients.","claim_ids":["c5"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"093b10575a3011a8ca851746d23f2966b18b41a4eed8231b51fa251506e9e185","hash":"f84851ac0a3291a80742b637b3e2c39f77d158967fa511d0b4017ac1430b3b8d","plain":"Coverage written for readers with the disease, reporting on the sarcoidosis trial. It is an article about the study rather than the study, and it phrases the result more warmly than the paper does. Use it to find the trial, not to weigh it."},{"id":"s13","type":"news","url":"https://diaryofrecovery.com/ara/","title":"ARA 290 for Nerve Pain & Regeneration (first-person account)","quote":"I went from 3 weeks of being unable to put on pants or get in the car without stabbing pain, to zero pain.","claim_ids":["c10"],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"f84851ac0a3291a80742b637b3e2c39f77d158967fa511d0b4017ac1430b3b8d","hash":"0f5b177a8fc288fb0418fbe55e1e858a7be77fdebf767cdb86c9e9464b6eb267","plain":"One person writing about their own experience: weeks of stabbing pain, then none. No measurement, no comparison, and no way to separate the compound from time passing or from anything else being done at once."},{"id":"s14","type":"news","url":"https://www.prnewswire.com/news-releases/araim-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ara-290-for-the-treatment-of-sarcoidosis-300293773.html","title":"Araim Pharmaceuticals Receives FDA Orphan Drug Designation for ARA 290 (sarcoidosis)","quote":"Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis","claim_ids":[],"accessed_at":"2026-08-04T08:37:38.697Z","prev":"0f5b177a8fc288fb0418fbe55e1e858a7be77fdebf767cdb86c9e9464b6eb267","hash":"b89b162a10ac93e1f150c4daa7bfae3caf7ed22517c3c04923713d7308cfe020","plain":"A press release about a rare-disease designation. That status unlocks development incentives and confirms the condition is rare and unserved. It is not a finding that the compound does anything."},{"id":"s16","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/24136731/","title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Dahan 2013, Mol Med, PMID 24136731)","quote":"28 d of daily subcutaneous administration of ARA 290 in a group of patients with documented SNFLD significantly improves neuropathic symptoms.","_id":"w_3r3nc5tt","_ts":"2026-08-04T08:29:39.538Z","accessed_at":"2026-08-04T08:29:39.538Z","claim_ids":[],"prev":"b89b162a10ac93e1f150c4daa7bfae3caf7ed22517c3c04923713d7308cfe020","hash":"de3bc68542e4044279a6b7ddf77e686b918e538ad4bd323ad665a964fae8aafb","plain":"28 days of daily injections in people with confirmed small-fiber nerve loss, with symptom scores improving and corneal nerve density rising. This is the trial that put the compound on the map, and it remains small, short, and confined to one disease."},{"id":"s17","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/28475703/","title":"Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (Culver 2017, IOVS, PMID 28475703)","quote":"The placebo-corrected mean change from baseline CNFA at day 28 was 109 (95% CI, -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively.","_id":"w_0lml4x18","_ts":"2026-08-04T08:29:41.048Z","accessed_at":"2026-08-04T08:29:41.048Z","claim_ids":[],"prev":"de3bc68542e4044279a6b7ddf77e686b918e538ad4bd323ad665a964fae8aafb","hash":"e7302728547d630487b1121f8f819897e52b47b65f6701bafad45d562e823c5c","plain":"Three doses were tested. Only 4 mg separated from placebo. The 1 mg and 8 mg ranges both cross zero, so the highest dose did less than the middle one, which is a genuine oddity and an argument against assuming more is better."},{"id":"s18","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/25728128/","title":"Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin (Collino 2015, Pharmacol Ther, PMID 25728128)","quote":"Despite a short plasma half-life (~2min), pHBSP activates a molecular switch that triggers sustained biological effects.","_id":"w_2psxkgvx","_ts":"2026-08-04T08:29:41.329Z","accessed_at":"2026-08-04T08:29:41.329Z","claim_ids":[],"prev":"e7302728547d630487b1121f8f819897e52b47b65f6701bafad45d562e823c5c","hash":"49197a539bd8ef91840c6896e0f1e14f6a46fd50cd56bbdedf5ab6d63e6d1769","plain":"A review laying out the pharmacology puzzle: the peptide is out of the blood within minutes, yet the effects run far longer, because it flips a signalling switch rather than needing to stay present. An argument assembled from published work, not new data."},{"id":"s19","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/29549285/","title":"Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy (Brines 2018, Sci Rep, PMID 29549285)","quote":"Corneal confocal microscopy (CCM) is an ophthalmic imaging technique which non-invasively quantifies corneal nerve fiber density, branch density and length, and has comparable diagnostic and superior ability to identify nerve regeneration compared to skin biopsy.","_id":"w_gisuu5w6","_ts":"2026-08-04T08:29:41.786Z","accessed_at":"2026-08-04T08:29:41.786Z","claim_ids":[],"prev":"49197a539bd8ef91840c6896e0f1e14f6a46fd50cd56bbdedf5ab6d63e6d1769","hash":"2492cfd608866b6020c1a78bfcbd7805a15e7f9e870f190cbcb2c58cfdbbf65f","plain":"Establishes the measuring instrument, not the compound. Scanning nerves in the cornea detects regrowth at least as well as cutting a skin sample, which is why the trials leaned on it for their objective outcome."},{"id":"s20","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/26431906/","title":"Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action (Cerit 2015, Eur Neuropsychopharmacol, PMID 26431906)","quote":"the direction and the strength of its effects do not unequivocally support an antidepressant-like profile for ARA290.","_id":"w_fa8z6voh","_ts":"2026-08-04T08:29:42.174Z","accessed_at":"2026-08-04T08:29:42.174Z","claim_ids":[],"prev":"2492cfd608866b6020c1a78bfcbd7805a15e7f9e870f190cbcb2c58cfdbbf65f","hash":"3efb5ee4eeb5c84e9b8186101ce927f5a4460cd36e4d4d86c97dfc3ed80945cd","plain":"A negative result in a different direction. Tested for antidepressant-like effects in a human model of drug action, the pattern did not support one. It is here because mood has been floated as a use, and this is what happened when it was tried."},{"id":"s21","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/32674280/","title":"A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (Lois 2020, J Clin Med, PMID 32674280)","quote":"There was no improvement in mean change baseline-week 12 in BCVA (-2.9 + 5.0), CRT (10 + 94.6 microns), central retinal sensitivity (-0.53 + 1.9 dB) or tear production (-0.13 + 7.7 mm).","_id":"w_x8jacpnp","_ts":"2026-08-04T08:29:42.482Z","accessed_at":"2026-08-04T08:29:42.482Z","claim_ids":[],"prev":"3efb5ee4eeb5c84e9b8186101ce927f5a4460cd36e4d4d86c97dfc3ed80945cd","hash":"85b2a987bbf172905d4add2da3c60d7d223a2007461f40f22dddd4c800bd74ad","plain":"A phase 2 in swelling at the back of the eye from diabetes. Vision, retinal thickness, retinal sensitivity and tear production all failed to move across 12 weeks. A clean negative, and it marks a boundary on where the repair signal reaches."},{"id":"s22","type":"source","url":"https://clinicaltrials.gov/study/NCT06626971","title":"NCT06626971 - The Use of ARA290 for the Treatment of Diabetic Macular Oedema (TERMINATED, n=9)","quote":"Overall status: TERMINATED. Phase 2. Actual enrolment 9.","_id":"w_gx0aomve","_ts":"2026-08-04T08:29:42.818Z","accessed_at":"2026-08-04T08:29:42.818Z","claim_ids":[],"prev":"85b2a987bbf172905d4add2da3c60d7d223a2007461f40f22dddd4c800bd74ad","hash":"ef772329e4284ef16eebc70020b562d97f2d1220fd8259e33d80c78f8f05acc4","plain":"A second run at the same eye condition, stopped early with nine people enrolled. A terminated trial answers nothing either way. What it means is that the question stays open rather than resolved."},{"id":"s23","type":"source","url":"https://clinicaltrials.gov/study/NCT02070783","title":"NCT02070783 - Cognitive and Neural Effects of ARA290 (Leiden University Medical Center, n=36)","quote":"Phase 1/Phase 2, actual enrolment 36, condition: Depression. Completed February 2014.","_id":"w_jgsyljo4","_ts":"2026-08-04T08:29:43.212Z","accessed_at":"2026-08-04T08:29:43.212Z","claim_ids":[],"prev":"ef772329e4284ef16eebc70020b562d97f2d1220fd8259e33d80c78f8f05acc4","hash":"e1d0a9043062c3feac7f6512b916fc80d41c598fafcb6d1f32569d45cc60c541","plain":"A 36-person university study in depression, completed in 2014. It sits in the registry with no posted result, which is why the one published negative on mood is all there is to go on."},{"id":"s24","type":"source","url":"https://clinicaltrials.gov/study/NCT01933529","title":"NCT01933529 - Effects of ARA 290 in Prediabetes and Type 2 Diabetes (Karolinska, status unknown)","quote":"Overall status: UNKNOWN. Phase 2. Estimated enrolment 24.","_id":"w_8fl38gjv","_ts":"2026-08-04T08:29:43.838Z","accessed_at":"2026-08-04T08:29:43.838Z","claim_ids":[],"prev":"e1d0a9043062c3feac7f6512b916fc80d41c598fafcb6d1f32569d45cc60c541","hash":"098cdbfa24f52681dde8e6efa2893846a1940b4709cb35c930bdc182b485299e","plain":"A 24-person study in prediabetes and type 2 diabetes that the registry still lists as unknown status. Trials that go quiet are not neutral. The human record here is thinner than the count of registered studies makes it look."},{"id":"s25","type":"source","url":"https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191","title":"EU/3/13/1191 - EMA orphan designation for cibinetide for the treatment of sarcoidosis","quote":"L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (cibinetide). Date of designation: 7 October 2013. Sponsor: Araim Pharmaceuticals Europe Limited.","_id":"w_kxgwzujw","_ts":"2026-08-04T08:29:44.124Z","accessed_at":"2026-08-04T08:29:44.124Z","claim_ids":[],"prev":"098cdbfa24f52681dde8e6efa2893846a1940b4709cb35c930bdc182b485299e","hash":"f1c1c8255f490a044cecf18acd04f9a66245db2341de0e2b730cea0833a1f58b","plain":"The European rare-disease designation, and the place the full amino acid sequence sits in public. Designation is an incentive granted before benefit is shown, not a marketing approval."},{"id":"s26","type":"source","url":"https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721","title":"EU/3/16/1721 - EMA orphan designation for cibinetide for prevention of graft loss in pancreatic islet transplantation","quote":"Orphan designation granted 29 August 2016 for the prevention of graft loss in pancreatic islet transplantation.","_id":"w_qg20xvmw","_ts":"2026-08-04T08:29:44.421Z","accessed_at":"2026-08-04T08:29:44.421Z","claim_ids":[],"prev":"f1c1c8255f490a044cecf18acd04f9a66245db2341de0e2b730cea0833a1f58b","hash":"f517e31ae982c00468e43e89137fb6b6e573e05541814bfa2bb3bfd87244d0cf","plain":"A second European rare-disease designation, this one aimed at keeping transplanted insulin-producing cells alive. It shows where the developers pointed next. Like every such designation, it comes before proof of benefit."},{"id":"s27","type":"source","url":"https://www.prnewswire.com/news-releases/araim-pharmaceuticals-given-fda-fast-track-designation-to-ara-290-for-the-treatment-of-sarcoidosis-associated-small-fiber-neuropathy-280635872.html","title":"Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy (28 October 2014)","quote":"Fast Track Designation ... for new therapies that have the potential to treat serious conditions for which there is no approved treatment option.","_id":"w_rvdzirem","_ts":"2026-08-04T08:29:44.707Z","accessed_at":"2026-08-04T08:29:44.707Z","claim_ids":[],"prev":"f517e31ae982c00468e43e89137fb6b6e573e05541814bfa2bb3bfd87244d0cf","hash":"463c6264b1f5fe101c8adc9279bf50a2b4d83be0ca872aef8f3db8912e91a549","plain":"Fast-track status from the US regulator, which means a serious condition with nothing approved for it. It speeds review and signals unmet need. It is not a judgment about whether the compound works."},{"id":"s28","type":"source","url":"https://www.stopsarcoidosis.org/wp-content/uploads/SFN-ARA290.pdf","title":"Webinar transcript: Small Fiber Neuropathy and ARA-290 Results - Dr. Daniel Culver, Cleveland Clinic, 17 May 2017 (Foundation for Sarcoidosis Research)","quote":"By day 56 some of that goes back to the baseline. ... it looks like 28 days is probably not going to be enough to maintain a durable benefit.","_id":"w_t06dbbgd","_ts":"2026-08-04T08:29:45.000Z","accessed_at":"2026-08-04T08:29:45.000Z","claim_ids":[],"prev":"463c6264b1f5fe101c8adc9279bf50a2b4d83be0ca872aef8f3db8912e91a549","hash":"6a1f15ea0164c8b70fe49f50c09075023af8369fd1f2888844ab2519d41e407f","plain":"The trial investigator speaking in a public webinar, and the sharpest limit on this page: the gains had begun sliding back by day 56, and 28 days of dosing looks too short to hold a benefit. The longer study that would settle it has not been run."},{"id":"s29","type":"source","url":"https://pubmed.ncbi.nlm.nih.gov/24555851/","title":"ARA 290 for treatment of small fiber neuropathy in sarcoidosis (van Velzen 2014, Expert Opin Investig Drugs, PMID 24555851)","quote":"ARA 290 treatment was consistently associated with a significant improvement of neuropathic pain symptoms in sarcoidosis patients, evidenced by a decrease in pain scores on validated questionnaires.","_id":"w_igp53xov","_ts":"2026-08-04T08:29:45.331Z","accessed_at":"2026-08-04T08:29:45.331Z","claim_ids":[],"prev":"6a1f15ea0164c8b70fe49f50c09075023af8369fd1f2888844ab2519d41e407f","hash":"1eab26d44c60d8a4278f938a358c00747b3730d72bd8fd7030205cffb5563a2f","plain":"A specialist review pulling the sarcoidosis nerve-pain studies together and finding the drop in pain scores consistent across them. Consistency among small trials run by overlapping investigators is weaker evidence than one large independent trial."},{"id":"s30","type":"source","url":"https://www.prnewswire.com/news-releases/araim-pharmaceuticals-cibinetide-ara-290-regenerates-small-nerve-fibers-and-improves-neuropathic-clinical-symptoms-in-the-orphan-disease-of-sarcoidosis-300452818.html","title":"Araim Pharmaceuticals: Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis (2017)","quote":"cibinetide demonstrated significant nerve regrowth assessed by two different measures of nerve fiber regeneration, as well as reductions in pain and improvements in functional capacity.","_id":"w_cl0tn2s9","_ts":"2026-08-04T08:29:45.649Z","accessed_at":"2026-08-04T08:29:45.649Z","claim_ids":[],"prev":"1eab26d44c60d8a4278f938a358c00747b3730d72bd8fd7030205cffb5563a2f","hash":"a98989a6f085aa842dcd235095af98881ef432c9c18a65460f7e2001630b972e","plain":"The developer's own announcement of the 2017 results. The underlying numbers are in the peer-reviewed paper elsewhere on this page, and this is the sponsor's framing of them, which reads more confidently than the data do."},{"id":"s31","type":"source","url":"https://x.com/vedichi_/status/2077787145238913472","title":"X - @vedichi_ (Steady State), 16 July 2026 - anecdotal, skeptical","quote":"most of the ARA-290 data is small-fiber neuropathy, not compression. does the repair signalling do anything while the tunnel is still squeezing the nerve?","_id":"w_l4jdyv61","_ts":"2026-08-04T08:29:45.981Z","accessed_at":"2026-08-04T08:29:45.981Z","claim_ids":[],"prev":"a98989a6f085aa842dcd235095af98881ef432c9c18a65460f7e2001630b972e","hash":"de4de52e25ce9f16e9e6457d2eb9dbc2f0a3a37d549fe591840f177ec7680626","plain":"A skeptic naming the exact gap this page is about: the trial evidence sits in nerve disease, not in a nerve being physically squeezed. One person's post, but the question is the right one and no trial has answered it."},{"id":"s32","type":"source","url":"https://x.com/NewsDeskOne/status/2077929820760019113","title":"X - @NewsDeskOne (Scratch Off), 17 July 2026 - anecdotal, positive","quote":"Did a run of ara 290, seemed to make a difference in neuropathy and sensitivity in my feet. This was after a couple months of bpc and 500","_id":"w_kwmcmxun","_ts":"2026-08-04T08:29:46.271Z","accessed_at":"2026-08-04T08:29:46.271Z","claim_ids":[],"prev":"de4de52e25ce9f16e9e6457d2eb9dbc2f0a3a37d549fe591840f177ec7680626","hash":"aa6d2ae795dcb50d0d8ea36702b28b18ebc415647fafbcf625719b2027f86f8b","plain":"Reports better numbness and sensitivity in the feet after a course, but ran it on the back of two other peptides, so nothing here can be assigned to this one. No measurement and no baseline either."},{"id":"s33","type":"source","url":"https://x.com/BarbaraPaden/status/1938281042944872509","title":"X - @BarbaraPaden (Barbara Paden), 26 June 2025 - anecdotal, in progress","quote":"Ok. 2nd daily dose of ARA-290 peptides in. Experimental treatment for small fiber peripheral neuropathy. 6-8 weeks to go","_id":"w_s7jiha1w","_ts":"2026-08-04T08:29:46.637Z","accessed_at":"2026-08-04T08:29:46.637Z","claim_ids":[],"prev":"aa6d2ae795dcb50d0d8ea36702b28b18ebc415647fafbcf625719b2027f86f8b","hash":"25451f57a82739f505bd9201a2423544a8db8caca7d9d4c37a13a2b71659b9cb","plain":"Two daily doses in, six to eight weeks still to go. There is no outcome here at all. It is on the page as a marker that people are dosing themselves for nerve pain well outside any trial."},{"id":"s34","type":"source","url":"https://x.com/0xTrenbolone/status/2075641254810198018","title":"X - @0xTrenbolone, 10 July 2026 - anecdotal, cites the trial record","quote":"phase 2b rct, n=64, sarcoidosis-associated small fiber neuropathy: 4mg/day cibinetide raised corneal nerve fiber area vs placebo (p=0.012) over 28 days, correlating with less pain and better 6-minute walk distance.","_id":"w_4kj6m6f5","_ts":"2026-08-04T08:29:46.945Z","accessed_at":"2026-08-04T08:29:46.945Z","claim_ids":[],"prev":"25451f57a82739f505bd9201a2423544a8db8caca7d9d4c37a13a2b71659b9cb","hash":"bc8d5ea9696081b563fb4ca65f8b3b1603ce6af2e4be76f393d0bb96df23ef74","plain":"A post quoting the phase 2b numbers accurately, doses, endpoint and p-value intact. Its interest is in showing how the trial data travels secondhand. The primary paper is still the thing to read."},{"id":"s35","type":"source","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"Brines 2015 full text: pharmacokinetics, injection volume and adverse events in the type 2 diabetes trial (PMC4365069)","quote":"following 4 mg SC, a peak plasma level ~3 ng/mL (~2.4 nmol/L) was obtained with a terminal half-life of ~20 min ... Subjects self-injected active or placebo (0.5 cc total volume) subcutaneously into the anterior thigh using rotating injection sites.","_id":"w_0k8r3q3n","_ts":"2026-08-04T08:29:47.300Z","accessed_at":"2026-08-04T08:29:47.300Z","claim_ids":[],"prev":"bc8d5ea9696081b563fb4ca65f8b3b1603ce6af2e4be76f393d0bb96df23ef74","hash":"147e3dc4c198cc398066fc054405d1c174ef6fb171b80d854a9d832ec3ac139e","plain":"The practical detail behind the dosing: 4 mg under the skin of the thigh in half a millilitre, peaking near 3 ng/mL and clearing with a roughly 20-minute half-life. This is where the once-daily self-injection schedule used in the trials comes from."}]}